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OBJECTIVE—Because of reduced antioxidant defenses, -cells
are especially vulnerable to free radical and inﬂammatory dam-
age. Commonly used antirejection drugs are excellent at inhibit-
ing the adaptive immune response; however, most are harmful to
islets and do not protect well from reactive oxygen species and
inﬂammation resulting from islet isolation and ischemia-reperfu-
sion injury. The aim of this study was to determine whether
redox modulation, using the catalytic antioxidant (CA), FBC-007,
can improve in vivo islet function post-transplant.
RESEARCH DESIGN AND METHODS—The abilities of redox
modulation to preserve islet function were analyzed using three
models of ischemia-reperfusion injury: 1) streptozotocin (STZ)
treatment of human islets, 2) STZ-induced murine model of
diabetes, and 3) models of syngeneic, allogeneic, and xenogeneic
transplantation.
RESULTS—Incubating human islets with catalytic antioxidant
during STZ treatment protects from STZ-induced islet damage,
and systemic delivery of catalytic antioxidant ablates STZ-in-
duced diabetes in mice. Islets treated with catalytic antioxidant
before syngeneic, suboptimal syngeneic, or xenogeneic trans-
plant exhibited superior function compared with untreated con-
trols. Diabetic murine recipients of catalytic antioxidant–treated
allogeneic islets exhibited improved glycemic control post-trans-
plant and demonstrated a delay in allograft rejection. Treating
recipients systemically with catalytic antioxidant further ex-
tended the delay in allograft rejection.
CONCLUSIONS—Pretreating donor islets with catalytic antiox-
idant protects from antigen-independent ischemia-reperfusion
injury in multiple transplant settings. Treating systemically with
catalytic antioxidant protects islets from antigen-independent
ischemia-reperfusion injury and hinders the antigen-dependent
alloimmune response. These results suggest that the addition of
a redox modulation strategy would be a beneﬁcial clinical
approach for islet preservation in syngeneic, allogeneic, and
xenogeneic transplantation. Diabetes 59:1731–1738, 2010
H
ypoxia is the leading cause of -cell death
during islet isolation and transplantation (1),
with the highest percentage of islet graft loss
and dysfunction occurring just days after trans-
plantation (2,3). Because islets are a cellular transplant,
devoid of intrinsic vasculature (1,4), they are exceptionally
susceptible to ischemia-reperfusion injury. Islets are also
increasingly vulnerable because they have inherently de-
creased antioxidant capacity (5–10), making them prone
to oxidative/nitrosative/free radical damage. The antigen-
independent complexities of islet transplantation increase
the incidence of primary graft nonfunction and -cell
death, thus requiring protection for islets at early stages of
the transplant procedure (11).
In addition to antigen-independent innate-mediated in-
ﬂammatory injury, islet allografts are also plagued by the
antigen-dependent T-cell mediated alloimmune response,
which necessitates immunosuppressive drugs for allograft
survival. Commonly used antirejection drugs are excellent
at inhibiting the adaptive immune response, although most
are harmful to islets and do not protect well from reactive
oxygen species and inﬂammation during islet isolation and
ischemia-reperfusion injury (12–14). In their review, Bala-
murugan et al. (13) concluded that successful islet trans-
plantation in type 1 diabetes necessitates islet-sparing
immunosuppressive agents that combat recurrent autoim-
munity with low islet toxicity. Predominantly, the ﬁeld of
islet transplantation is devoid of cytoprotective agents that
promote islet survival and function by inhibiting nonspe-
ciﬁc innate-mediated inﬂammation during islet isolation
and early inﬂammatory events in islet transplantation
(11,13,15–19).
The ﬁrst phase of immunity involves innate immune
activation and subsequent proinﬂammatory signals re-
quired for optimal adaptive immune function (20–22), yet
the majority of immunosuppressive drugs only target
adaptive immune function (17,23), the second phase of
immunity. A nontoxic, cell-permeable catalytic antioxidant
(CA) redox modulator, FBC-007 [manganese(II) tetrakis
(N-ethylpyridium-2-yl)porphyrin], is able to depress free
radical and cytokine production by antigen-presenting
cells (24) and T cells in transgenic and allospeciﬁc mouse
models (20,25). Additionally, redox modulation inhibits
cytotoxic lymphocyte target cell lysis by reducing the
production of intracellular cytolytic molecules (perforin
and granzyme B) in a mixed leukocyte reaction without
toxicity (25), preserves and promotes human islet function
in vitro (15,16), prevents the transfer of diabetes into
young NOD.scid mice (26), and inhibits innate-immune
nuclear factor (NF)-B activation (24). Thus, islet-sparing
agents, which decrease the production of free radicals
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tive impact on islet function post-transplant.
Because islet transplantation can beneﬁt from agents
that inhibit early inﬂammatory cascades to preserve islet
function (18), we hypothesize that redox modulation holds
potential as a therapy in islet transplantation to decrease
the incidence of -cell primary nonfunction. To further
test the effects of redox modulation using CA we treated
human islets with streptozotocin (STZ) in vitro and treated
mice in vivo with STZ, both in the presence or absence of
CA, to mimic antigen-independent free radical damage and
inﬂammation of post-transplant ischemia-reperfusion in-
jury. To examine the effects of islet-directed CA treatment
on innate-mediated (antigen-independent) primary islet
nonfunction in vivo, we performed syngeneic (175 islets/
recipient), suboptimal syngeneic (100 islets/recipient), al-
logeneic (300 islets/recipient), and xenogeneic (400–500
islets/recipient) islet transplants to assess islet function.
Additionally, we performed (300 islets/recipient) islet
transplants in diabetic recipients to assess islet function
in the presence or absence of systemic redox modula-
tion in an allogeneic transplant setting inclusive of both
innate (antigen-independent) and adaptive (antigen-de-
pendent) immune responses. Our results demonstrate
that islet-directed and systemically delivered redox
modulation, administered in the absence of an addi-
tional immunosuppressive regimen, preserve islet func-
tion post-transplant.
RESEARCH DESIGN AND METHODS
Human islets. Human pancreata were obtained from CORE (Center for
Organ Recovery and Education, Pittsburgh, PA) and were harvested using
standard multiorgan recovery techniques, and islets were isolated as previ-
ously described (15).
In vitro human islet experiments. Islet preparations were cultured in ﬂasks
at 37°C in an atmosphere of 5% CO2 in humidiﬁed air in human islet medium
containing CMRL-1066 (Gibco-BRL, Carlsbad, CA), 5.5 mmol/l low glucose
medium supplemented with 10% FCS, 100 units/ml penicillin, 0.1 mg/ml
streptomycin, and 2 mmol/l L-glutamine (Life Technologies, Grand Island, NY).
Human islets were available to us after 3 days of culture. The islets were
hand-picked on the fourth day using a dissecting microscope. Groups of 60
hand-picked islets were randomized to control and experimental groups. Each
group was subcultured in 60  15-mm Falcon dishes at a concentration of 12
islets/ml for8hi nt h epreviously described islet media. The catalytic
antioxidant group was treated with 68 mol/l CA and the STZ group was
treated with 11 mmol/l STZ, whereas the control group was cultured in islet
media alone. The group treated with CA and STZ was treated with 68 mol/l
CA 20 min before the addition of 11 mmol/l STZ. We chose the dose of 68
mol/l FBC-007 for use in these experiments based on the ability of FBC-007
to scavenge superoxide compared with the native manganese superoxide
dismutase (MnSOD). On a per mass basis, 34 mol/l is the concentration of
FBC-007 that is needed to have the same activity as the endogenous MnSOD
enzyme in most cells, save islet -cells, which have reduced levels of MnSOD.
We saw a beneﬁt in doubling the dose of this nontoxic compound to 68 mol/l
for our studies.
Human islet viability. Islet viability was determined by simultaneous
staining of live and dead cells using a two-color ﬂuorescence assay (acridine
orange (green  live) and ethidium bromide (red  dead); Sigma, St. Louis,
MO). After the 8-h incubation, all islets from each group were transferred into
separate microcentrifuge tubes, washed with PBS, and spun at 2000 rpm for 2
min. Supernatants were carefully aspirated, leaving 25 l to allow resuspen-
sion of the cell pellets. Next, 1.3 l of dye mix (100 g/ml acridine orange 
100 g/ml ethidium bromide in PBS) was added to each tube to stain all islet
cell nuclei. The tube was mixed gently, 25 l cell suspension was transferred
to a microscope slide, and a cover slip was placed on top of the suspension.
Cells were visualized at 10 magniﬁcation using a ﬂuorescence microscope
with an excitation of 450–490 nm. At least three ﬁelds from each group were
analyzed by ImageJ (National Institutes of Health, Bethesda, MD) software.
The percentage of viable and dead cells was determined by linearly converting
ImageJ arbitrary units into percentages.
Mice. Male 6–8 week old C57BL/6 and BALB/c mice were purchased from
The Jackson Laboratory (Bar Harbor, ME). C57BL/6-Ins2
Akita/ breeder pairs
(female C57BL/6  male C57BL/6-Ins2
Akita/) were also purchased from The
Jackson Laboratory but bred in-house at the Rangos Research Center (Pitts-
burgh, PA). Male C57BL/6-Ins2
Akita/ mice develop spontaneous diabetes by 4
weeks of age and do not require exogenous insulin or ﬂuids/electrolytes to
thrive. This strain is well suited for transplantation studies due to their ease of
care, lack of exogenous diabetes induction (STZ), and ability to be rendered
indeﬁnitely euglycemic via syngeneic islet transplants (300 C57BL/6 islets), yet
reject islet transplants from major histocompatibility complex (MHC)-mis-
matched donors (300 BALB/c islets) (27).
Systemic treatment with catalytic antioxidant to inhibit STZ-induced
diabetes. C57BL/6 male mice were injected intraperitoneally with 10 mg/kg
CA for 7 days. On day 2, all mice were given an intravenous injection of 170
mg/kg STZ. Blood glucose was measured every other day. Two consecutive
blood glucose readings 300 mg/dl were indicative of STZ-induced diabe-
tes. Diabetic animals were killed after the second consecutive reading.
Syngeneic transplants. Eight to twelve week old C57BL/6 male mice were
used as donors and recipients. Recipients were injected intraperitoneally with
240 mg/kg STZ (Sigma) on day 1. Animals were tested for diabetes using urine
test strips (Bayer) on day 3. All diabetic animals received 1 unit of insulin
(Lantus) and 500 l of Ringer solution on days 3–5. On day 5, islets were
isolated from naive donor C57BL/6 mice as described in Bertera et al. (28).
The same day, islets were simultaneously picked, counted, and redistributed
into Petri dishes containing 175 islets each. Each dish of islets contained islet
media (10% heat-inactivated FBS, 2% 1 mmol/l HEPES, 10,000 mg/ml 1%
penicillin/streptomycin, 200 mmol/l 1% L-glutamine, and 50 mol/l 0.1%
2--mercaptoethanol in RPMI 1640 sterile-ﬁltered) alone or islet media plus 68
mol/l catalytic antioxidant. Treated and control islets were incubated for
24 h at 37°C and 5% CO2. Nonfasting blood glucose levels were tested in
recipient mice on day 6 by obtaining a small blood sample from the
retro-orbital sinus. Only animals with blood glucose 400 mg/dl were used as
recipients. On day 6, each recipient was transplanted with 100 or 175
syngeneic CA-treated or untreated control islets inserted under the kidney
capsule as described in Bertera et al. (28).
Recipients of 100 untreated or catalytic antioxidant-treated syngeneic
islets had their blood glucose monitored approximately every other day for
19 days. Recipients of 175 islets were subject to a fasting intraperitoneal
glucose tolerance test (IPGTT) on postoperative days 9 and 70). Food was
removed from the recipients’ cages 18 h before IPGTT with water available
ad libitum. Mice were weighed and a baseline (0-min) blood glucose was
taken immediately before each recipient was injected with a 10 l/g body
wt dose of sterile-ﬁltered 20% glucose solution in distilled H2O. Blood
glucose readings were taken at 30, 60, 90, and 120 min after glucose
injection. Nephrectomies were performed on day 77 as described in
Bertera et al. (29).
Islet-directed CA treatment to delay allograft rejection. Male C57BL/6
mice were used as transplant recipients, and male BALB/c mice were used as
islet donors. C57BL/6 mice were rendered diabetic and recipients were
prepared for transplant as previously described. Islets were incubated in islet
media alone or in islet media with 68 mol/l catalytic antioxidant for 24 h.
Three hundred CA-treated or control-treated BALB/c islets were transplanted
under the kidney capsule of diabetic C57BL/6 recipients as previously
mentioned. All diabetic recipients became euglycemic post-transplant. Blood
glucose was checked every other day. Two consecutive blood glucose
readings 400 mg/dl were indicative of allograft rejection. Diabetic animals
were euthanized after the second consecutive reading.
In vivo human islet experiments: xenotransplants. Immediately after
isolation, human islets were cultured in human islet medium with or without
the addition of 68 mol/l CA for 30–40 h before transplanting 400–500
untreated or CA-treated islets into diabetic C57BL/6 mice in the absence of
additional immunosuppression. Two human pancreata were used for these
experiments; however, the islets were not pooled together. Each recipient
animal only received islets from one donor to add the variable of islet quality
disparity among donors to our experiment. All C57BL/6 animals were ren-
dered diabetic and transplanted with islets as previously mentioned. Recipient
blood glucose levels were tested daily for 7 days post-transplant and then
euthanized.
Systemic delivery of CA in pellet form to delay allograft rejection. Male
C57BL/6-Ins2
Akita/ mice were used as transplant recipients, and male BALB/c
mice were used as islet donors. This work is based on Matthews et al. (27),
and the transplants were performed as previously mentioned, transplanting
300 BALB/c islets into each spontaneously diabetic C57BL/6-Ins2
Akita/ recip-
ient on day 0. Three days before transplant, a placebo or 21-day CA pellet (0.1
mg/day or 5 mg/kg/day) (Innovative Research of America, Sarasota, FL) was
inserted into each recipient. An additional pellet was inserted into mice on
postoperative day 16, as pellets were administered every 20 days. All diabetic
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every other day. Two consecutive blood glucose readings 400 mg/dl were
indicative of allograft rejection. Diabetic animals were euthanized after the
second consecutive reading.
Hematoxylin and eosin staining of islet-bearing kidneys. Mouse kidney
samples were ﬁxed in 4% paraformaldehyde for 3 h and then transferred to
30% sucrose. After being imbedded in frozen section medium (Richard-
Allan Scientiﬁc, Kalamazoo, MI), cryosections (10 m) were cut using a
cryostat (Microm Cryostar HM550 Cryostat, Thermo Fisher Scientiﬁc,
Waltham, MA) and mounted onto gelatin-coated or precleaned slides.
Hematoxylin and eosin staining was performed using a frozen section
staining kit (Thermo Electron, Pittsburgh, PA). Images were captured at
40 magniﬁcation using a Nikon confocal microscope (D-ECLIPSE C1,
Nikon, Tokyo, Japan).
Statistical analysis. Data are expressed as means 	 SEM. The difference
between mean values was determined by a Student t test for singular
comparisons and by one-way ANOVA for multiple comparisons. The area
under the curve was determined using the trapezoidal rule. Kaplan-Meier
survival plots were analyzed by the log-rank test. All statistical analysis was
performed with the aid of PRISM (GraphPad, San Diego, CA) and JMP
statistical software from the SAS Institute using P 
 0.05 to achieve
signiﬁcance.
RESULTS
CA protects human islets from STZ-induced cell
death. In vitro STZ treatment was used to mimic ischemia-
reperfusion injury in human islets to examine the ability of
CA treatment to protect from islet cell death. For this
experiment, human islets were divided into four groups: 1)
media alone (untreated), 2) CA, 3) STZ, or 4)C A STZ.
After an 8-h incubation, a double-ﬂuorescence viability
assay was performed using acridine orange, which pene-
trates the plasma membrane of living cells and stains their
nuclei green, and ethidium bromide, which only penetrates
dead cells, in which membrane integrity is compromised,
to stain their nuclei red. Panels in Fig. 1A are representa-
tive ﬂuorescent images from each treatment group corre-
lating to quantitative data analysis graphed in Fig. 1B.A
substantial decrease in viability was recorded when islets
were treated with STZ. As we hypothesized, islets treated
with STZ in the presence of CA demonstrated a signiﬁcant
increase in cell viability versus islets treated with STZ
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FIG. 1. Catalytic antioxidant (CA) protects human islets from STZ-
induced cell death. Human islets (60 islets/group) were cultured in
media alone, 68 mol/l catalytic antioxidant, 11 mmol/l STZ, or 68
mol/l catalytic antioxidant  11 mmol/l STZ. A: Representative images
of each group of islets after an 8-h incubation, stained with acridine
orange (green/live) and ethidium bromide (red/dead) and then visual-
ized under a ﬂuorescence microscope at 10 magniﬁcation. B: The
percentages of live islet cells from (A) were assessed by ImageJ
software (n > 3). Data are presented as means  SEM. Signiﬁcance was
tested using one-way ANOVA (**P < 0.05). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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protects human islets when used in the media alone and,
even more signiﬁcantly, when islets are treated with CA in
the presence of STZ, a model of free-radical induced cell
death.
Systemic treatment with CA inhibits STZ-induced
diabetes. STZ induces diabetes through a nitric oxide free
radical mechanism resulting in DNA damage and islet cell
death (30). Because CA can inhibit free radical damage
(20,24,25,31), we wanted to determine whether systemic
catalytic antioxidant treatment could protect islets from
STZ-induced diabetes. Five C57BL/6 mice were injected
with 10 mg/kg CA daily for 7 days, and nine C57BL/6 mice
were used as untreated controls. On day 2, all mice were
injected with STZ. As shown in Fig. 2, untreated mice (n 
9) developed diabetes (2.3 	 0.6 days), whereas none of
the CA-treated mice (n  5) developed diabetes (120
days) (log-rank test, P  0.005). These results demonstrate
that systemic treatment with CA protects islets from free
radical damage to prevent STZ-induced diabetes.
Islets incubated with CA before syngeneic transplant
exhibit increased function. On the basis of previously
published data demonstrating improved islet mass, viabil-
ity, and function when human islets are treated with CA
treatment during or after isolation (15,16), we wanted to
determine whether islet-directed CA could improve graft
function in syngeneic transplant models. Diabetic C57BL/6
recipients were transplanted with 175 syngeneic islets,
which were previously incubated in the presence (n  5)
or absence (n  5) of 68 mol/l CA for 24 h. All animals
were rendered euglycemic after transplant and sustained
long-term euglycemia. After nephrectomy, all transplant
recipients reverted to diabetes (data not shown). Fasting
IPGTT were performed on post-operative days 9 and 70.
Recipients of CA-treated islets demonstrated signiﬁ-
cantly improved glycemic control at 30 and 60 min time
points compared with untreated controls (Fig. 3A). Spe-
ciﬁcally, the area under the curve for recipients of CA-
treated islets was less than one-half (4,561.4 	 1,054.2 min 
mg
1  dl
1) of the area under the curve for recipients of
untreated islets (10,828.8 	 1,336.1 min  mg
1  dl
1) (Fig.
3B). To observe any long-lasting effect of the CA incuba-
tion on islet function, mice from each group were moni-
tored long-term and another IPGTT was performed on day
70. Although the 70-day IPGTT did not show statistical
signiﬁcance, the trend of improved glycemic control in
recipients of CA-treated islets, namely, at 30 and 60 min,
was maintained (Fig. 3C).
We also performed suboptimal syngeneic transplants
where diabetic C57BL/6 mice received 100 islets treated in
the presence (n  5) or absence (n  5) of 68 mol/l CA
for 24 h. We monitored the blood glucose levels of both
groups for 3 weeks post-transplant and observed signif-
icantly decreased blood glucose levels in the recipients of
100 CA-treated islets compared with recipients of un-
treated islets (Fig. 3D). Speciﬁcally, the most signiﬁcant
divergence of islet function occurred 10–20 days post-
transplant, during islet engraftment under the kidney
capsule (32). The protective effects of redox modulation
are further evidenced by an IPGTT performed 4 weeks
post-transplant, which demonstrates improved glycemic
control for recipients of a suboptimal number of CA-
treated islets (supplementary Fig. 1, available in an
online appendix at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-0588/DC1). These results corrobo-
rate that islet-directed CA treatment is able to suppress
antigen-independent ischemia-reperfusion injury and per-
haps promote islet engraftment as demonstrated by im-
proved islet graft function.
Islet-directed CA treatment delays allograft rejec-
tion in an MHC-mismatched islet transplant model.
Next, we tested the ability of islet-directed redox modula-
tion to improve islet allograft survival. Because islet-
directed CA treatment can improve islet function against
antigen-independent ischemia-reperfusion injury in a syn-
geneic transplant model (Fig. 3) and in human islet isola-
tion (15,16), we wanted to determine whether islet-
directed redox modulation using catalytic antioxidant
could delay antigen-dependent allograft rejection. These
experiments were performed using BALB/c (H-2d) donor
islets incubated in the presence or absence of 68 mol/l
catalytic antioxidant for 24 h. Three hundred CA-treated or
untreated islets were transplanted into diabetic C57BL/6
(H-2b) recipients.
Post-transplant, recipients of CA-treated islets (73.0 	
2.6) normalized (n  5) to signiﬁcantly lower blood
glucose levels compared with recipients (n  5) of control
islets (118.2 	 3.7) (Fig. 4A), indicative of an increase in
early islet graft survival. Although all allograft recipients
were euglycemic for 2 weeks (range of 65–175 mg/dl),
recipients of CA-treated islets retained euglycemia, and
thus a functioning allograft, signiﬁcantly (log-rank test,
P  0.0132) longer (31.8 	 7.1 days) than the recipients of
untreated islets (21.4 	 1.0 days) (Fig. 4B). Taken to-
gether, these data indicate that islet-directed CA treatment
alone can delay allograft rejection.
Islet-directed CA treatment improves islet function
in xenogeneic transplantation. To more stringently
analyze islet-directed redox modulation in ischemia-reper-
fusion injury, we performed xenogeneic transplants. Hu-
man islets were incubated in the presence or absence of 68
mol/l CA for 30–40 h post-isolation, and then 400–500
untreated or CA-treated islets were transplanted into
diabetic C57BL/6 recipients under the cover of no addi-
tional immunosuppression to fully assess the efﬁcacy of
CA to inhibit innate immune-derived primary graft dys-
function in a xenograft model. One control animal died
between days 2 and 3 (black arrow) before the completion
of the experiment, whereas the average blood glucose of
recipients of catalytic antioxidant-treated islets was signif-
icantly lower compared with recipients of untreated islets
(Fig. 5). We suspect that our data would reﬂect even
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FIG. 2. Systemic catalytic antioxidant (CA) treatment inhibits STZ-
induced diabetes. Mice received CA treatment on days 1–7, and STZ
was given on day 2. f, untreated (n  9); ‚, CA treated (n  5).
Signiﬁcance was tested using the log-rank test (P  0.0005).
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constrained by a maximum reading of 600 mg/dl, as all
glucometer readings of “HIGH” were recorded as 600
mg/dl. Four of ﬁve recipients of untreated islets had
postrejection blood glucose readings of HIGH. Compara-
tively, all recipients of CA-treated islets remained 
500
mg/dl throughout the experiment, indicative of enhanced
islet function for recipients of islets pretreated with CA.
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FIG. 3. Pretreating islets with catalytic antioxidant (CA) before syngeneic transplant improves islet function. Islets were incubated with CA or
remained untreated for 24 h. Syngeneic recipients were transplanted with 175 untreated or CA-treated islets (A–C). For suboptimal syngeneic
experiments 100 untreated or 100 CA-treated islets were transplanted into syngeneic recipients (D). A: Fasting IPGTT performed on
postoperative day 9. f, untreated islets (n  5); ‚, CA-treated islets (n  5). B: Area under the curve calculation for (A). Signiﬁcance was tested
using a Student t test (**P < 0.05). C: Fasting IPGTT performed on postoperative day 70. f, untreated islets (n  3); ‚, CA–treated islets (n 
3). D: Blood glucose readings from recipients of 100 CA-treated or untreated islets within 3 weeks of suboptimal syngeneic transplant. f,
untreated islets (n  5); ‚, CA–treated islets (n  5). Signiﬁcance was tested using one-way ANOVA (**P < 0.05).
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FIG. 4. Pretreating islets with catalytic antioxidant (CA) before allogeneic transplant improves islet function. Islets were incubated with CA for
24 h, and then 300 untreated or CA-treated islets were transplanted into allogeneic recipients. A: Normalization blood glucose of recipients
within 2 postoperative days. Signiﬁcance was tested using a Student t test (**P < 0.05). B: Allograft survival of recipients. f, untreated islets
(n  5); ‚, CA–treated islets (n  5). Signiﬁcance was tested using a log-rank test (P  0.0132).
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effective islet preservation strategy if/when the limited
availability of allogeneic islets is overcome by using xeno-
geneic islets.
Systemic delivery of CA prolongs allograft function
in an MHC-mismatched islet transplant model. To
determine whether systemic administration of CA would
equate to a more substantial delay in allograft rejection,
we transplanted 300 BALB/c islets into spontaneously
diabetic C57BL/6-Ins2
Akita/ mice (27). In our colony, 7- to
8-week-old diabetic C57BL/6-Ins2
Akita/ males have a
blood glucose level of 580 	 19 mg/dl, which is compara-
ble to the average blood glucose level (544 	 11 mg/dl) for
the same mice housed at The Jackson Laboratory. Three
days before transplant, a catalytic antioxidant (21-day, 5
mg/kg/day) or placebo pellet was inserted into diabetic
recipients. All 10 recipient mice normalized posttransplant
(125 	 16.94 mg/dl). CA-treated recipients (n  5) dis-
played a signiﬁcant increase (log-rank test, P  0.0023) in
graft function (25.6 	 2.9 days) compared with untreated
recipients (n  5) (14.4 	 0.2 days) (Fig. 6A). Hematoxylin
and eosin sections of islet-bearing kidneys postrejection
demonstrate a pronounced inﬁltrate in untreated recipi-
ents and a sparse inﬁltrate in CA-treated recipients (Fig.
6B), suggesting the delay in graft rejection with CA treat-
ment is associated with decreased migration of immune
cells to the site of the graft. These results demonstrate that
systemic delivery of CA can delay graft rejection by
depressing the cytotoxic free radical and inﬂammatory
damage generated by the innate (antigen-independent)
immune response and possibly by impacting the T-cell-
mediated adaptive (antigen-dependent) immune response
(20,25) to hinder allograft rejection.
DISCUSSION
Allograft acceptance can be achieved using immunosup-
pressive drugs, although most drugs that inhibit T-cell–
mediated graft destruction have the unfortunate side effect
of islet toxicity and do not signiﬁcantly protect islets from
ischemia-reperfusion insults (12–14), leading to primary
nonfunction and -cell death. Current literature in islet
transplantation expresses a need for improved therapeutic
agents that control rejection while preserving islet func-
tion through cytoprotection (11,13,15–18,33,34). Because
redox modulation affects the innate and the adaptive
immune responses (20,24,25) and demonstrates cytopro-
tection during human islet isolation (15,16), we hypothe-
sized that it may be a useful approach in islet
transplantation. Because only a fraction of transplanted
islets survive ischemia-reperfusion injury (3,15,16), our
current study used the well-described redox modulator,
CA (FBC-007), to determine whether islet graft survival
and function could be improved by inhibiting free radical
and inﬂammatory damage.
In this study, CA protects islets from STZ-induced free
radical damage and antigen-independent inﬂammatory
ischemic damage in syngeneic, allogeneic, and xenogeneic
transplantation and delays rejection in allogeneic trans-
plantation. Speciﬁcally, we used STZ-induced diabetes as a
model of islet cell death and found that systemic delivery
of CA protected all mice from STZ-induced diabetes (Fig.
2), probably by increasing antioxidant defenses in islets to
render them more resistant to STZ-induced free radical
damage. To isolate antigen-independent ischemia-reperfu-
sion injury in a transplant setting, we used syngeneic
transplant models to analyze the effects of pretreating
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FIG. 5. Pretreating islets with catalytic antioxidant (CA) before
xenogeneic transplant improves islet function. Human islets were
incubated in the presence or absence of CA for 30–40 h. Then, 400–500
untreated or CA–treated human islets were transplanted into xenoge-
neic diabetic C57BL/6 recipients. f, untreated islets (n  5); ‚,
CA–treated islets (n  5). The black arrow represents the death of a
transplant recipient in the untreated islet group. For the remainder of
the study, n  4 for the untreated islet group. Signiﬁcance was tested
using the Student t test (**P < 0.05).
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FIG. 6. Systemic catalytic antioxidant (CA) treatment delays allograft
rejection. Recipients were treated with a placebo or CA pellet 3 days
before transplant and then 300 allogeneic islets were transplanted into
all recipients. A: Allograft survival of recipients. f, placebo pellet (n 
5); ‚, CA pellet (n  5). Signiﬁcance was tested using a log-rank test
(P  0.0023). B: Post-rejection hematoxylin and eosin staining repre-
sentative of untreated and CA-treated recipients. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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islet-directed CA is protective of islet function (Fig. 3A–D).
Antigen-independent injury by the innate immune sys-
tem plays a larger role in allograft rejection than previ-
ously thought, correlating to the activation state of the
powerful redox-dependent transcription factor, NF-B.
NF-B shapes the innate and adaptive immune responses
(35–40) by controlling a myriad of proinﬂammatory and
proapoptotic genes in multiple cell types, including -cells
(41–43). Our previously published work indicates that
redox modulation using CA can hinder apoptotic and
necrotic pathways by inhibiting NF-B-DNA binding, poly-
(ADP-ribose) polymerases activation, and the production
of chemokines and cytokines in human islets (16). In this
study, we expanded our previous work with human islets
(15,16) using STZ treatment in the presence or absence of
redox modulation by catalytic antioxidant to mimic islet
cell damage prevalent in ischemia-reperfusion injury. This
data demonstrated redox modulation is protective in a
robust setting of ischemia-reperfusion injury (Fig. 1),
probably by hindering the previously mentioned apoptotic
and necrotic pathways. Other studies have also sighted
NF-B in islet death, demonstrating that manipulating
components of the NF-B pathway to hinder its activation
and imminent inﬂammatory damage, can protect islets
from apoptosis in autoimmunity and islet transplantation
(43–45). Because redox modulation using CA can enter
mitochondria in vivo to impart antioxidant protection (31),
preservation of mitochondrial function and, therefore,
ATP is a potential mechanism by which CA protects from
-cell death (25). Using redox modulation to treat the
recipient (Figs. 2 and 6) and/or the donor islets (Figs. 1, 3,
and 5) would limit -cell exposure to cytokine and nitric
oxide damage, thus hindering the hypoxic and inﬂamma-
tory onslaught endured by islets during isolation and
post-transplantation.
Moreover, Contreras et al. (46) noted that increasing
islet yield post-isolation is paramount to propelling the
success of clinical islet transplantation, as the Edmonton
protocol requires one to three pancreata per recipient.
Currently, the demand for islets far outweighs the supply
(46), especially because more than one islet infusion is
frequently required to eliminate the need for exogenous
insulin for any time period (47). Because CA-treatment
increased islet viability in human islets in vitro (Fig. 1)
(15,16) and in murine in vivo (Figs. 1–5) models of
syngeneic, allogeneic, and xenogeneic (human) ischemia-
reperfusion injury, CA treatment may allow a reduced
number of islets to normalize a recipient. The ability to
decrease the number of human pancreata/islet infusions
required to achieve long-term insulin independence would
overcome a major hurdle in islet transplantation (46–48).
Additionally, it has been reported that rodent islets have
decreased protection from oxidative stress compared with
human islets (49). This evidence suggests that our favor-
able results using redox modulation in syngeneic and
allogeneic murine models of transplantation may translate
successfully to allogeneic clinical transplantation.
In addition to reducing primary islet nonfunction in
syngeneic (Fig. 3), allogeneic (Fig. 4), and xenogeneic
models (Fig. 5), islet-directed CA treatment also delayed
antigen-dependent allogeneic islet transplantation (Fig. 4).
Comparatively, systemic delivery of CA (Fig. 6) extends
allograft rejection beyond islet-directed catalytic antioxi-
dant treatment to support islet engraftment, viability, and
function because CA can also act as an immunomodula-
tory agent by inhibiting antigen-presenting cell activation
(24), CD4 (20) and CD8 T-cell effector function (25), and
cytotoxic lymphocyte target cell lysis by decreasing cyto-
lytic effector molecule production in transgenic and allo-
reactive models (25). However, in this study, we are not
certain if the delay in allograft rejection is due to increased
cytoprotection and preservation of islets by catalytic anti-
oxidant during ischemia-reperfusion injury (Figs. 3 and 4)
or as a result of immune modulation correlating to de-
creased alloimmune-related inﬂammation and a subse-
quent decrease in migration of immune cells to the sight of
the graft in CA-treated recipients (Fig. 6). Most likely, the
delay in allograft rejection is a combination of the two.
CA is known to promote islet (15,16) and cell survival
while inhibiting effector function (20,25); however, studies
examining the effects of redox modulation on -cell pro-
liferation and genes that regulate proliferation are yet to
be performed. Because CA inhibits primary immunogenic
proliferation (20,25) and sustains disruption of effector
function, but does not signiﬁcantly inhibit secondary ex-
pansion (20), redox modulation could be of beneﬁt when
coupled to noncalcineurin or mammalian target of rapa-
mycin targeted antiproliferative drugs, like mycophenolate
mofetil in syngeneic, allogeneic, and xenogeneic trans-
plants of vascularized or nonvascularized tissue. Addition-
ally, if islets are treated with CA before transplant, they
may be afforded increased protection from toxic immuno-
suppressive agents currently used in transplant protocols,
thereby increasing transplant success by limiting graft
loss. Redox modulation may also allow for the dose and
duration of immunosuppressants to be weaned over a
transplant recipient’s lifetime because CA protects from
the inﬂammatory damage associated with islet isolation
and transplantation.
Taken together, redox modulation is a favorable therapeu-
tic agent to add to the currently administered immunosup-
pressives because CA is a nontoxic, nonimmunogenic small-
molecule compound that offers the ﬂexibility of systemic
and/or tissue-speciﬁc treatment, ease of application, and
a history of reproducible outcomes (15,16,20,24–26,31).
The reported beneﬁts of CA treatment for islets, autoim-
munity, and alloimmunity suggest redox modulation as a
clinical approach, especially for diabetic recipients of islet
allografts.
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